Trilaciclib is a potential first-in-class short-acting CDK4/6 inhibitor in development to preserve hematopoietic stem cells and enhance immune system function during chemotherapy. Trilaciclib is administered intravenously prior to chemotherapy and has the potential to significantly improve treatment outcomes.
G1 is currently evaluating trilaciclib in three Phase 2 clinical trials: two studies in patients with small-cell lung cancer (SCLC), and one study in patients with triple-negative breast cancer (TNBC). Preliminary data from the SCLC trials were presented at the American Association for Cancer Research 2016 Annual Meeting and at the 2016 World Conference on Lung Cancer (see: Publications).
Data from a Phase 1 trial in healthy volunteers were presented at the American Society of Clinical Oncology 2015 Annual Meeting. Trilacicilib has been extensively studied in animals; these preclinical data have been presented at several scientific meetings and published.